Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli, Fikri; Altundag, Kadri; AKBULUT, HAKAN; PAYDAŞ, SEMRA; BAŞARAN, GÜL; SAİP, Pınar; Dogu, Gamze; Erlap, YEŞİM; Uslu, Ruchan; Sevinc, Alper; Onur, Handan; Mandel, Nil; Sezgin, Canfeza; Altinbas, Mustafa; Guler, Nilufer; Isikdogan, Abdurrahman; Gokmen, Erhan; Uygun, Kazim; Ustuner, Zeki; Yaren, Arzu; Demirkan, Binnaz; Coskun, Ugur; Ata, Alper; Ozkan, Metin; Arican, Ali

doi:10.1007/s12282-013-0506-y

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., ...Daha Fazla

BREAST CANCER, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1007/s12282-013-0506-y
Dergi Adı: BREAST CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.480-485
Anahtar Kelimeler: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.